A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (MSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer